Divi’s Laboratories Reports 64% Rise in Q2 Profit as Revenue Climbs 35%

Synopsis

Divi's Laboratories made a net profit of ₹1,127 crore in the September quarter, 63.57% higher than the previous quarter's net profit of ₹689 crore, on a revenue of ₹3,676 crore, which was 35.39% higher. The active pharmaceuticals manufacturer (APM) is now reporting two strong quarters, as its first-half profit comes in at ₹2,029 crore. Costs increased at a lesser rate than revenues, resulting in higher operating margins.

The 1st term in the decimal system

In the second quarter of 2026-27, the net profit of Divi's Laboratories was up by 63.57% to ₹1,127 crore from what it was in the corresponding quarter of the previous year, as its brand products saw high demand. Revenue from operations rose 35.39% to ₹3,676 crore, from ₹2,715 crore. Spending on services jumped 16% from ₹1,948 crore to ₹2,265 crore, but still lagged behind the revenue growth. The company announced the results on Saturday, Nov. 7.

The second quarter has come on the heels of a first quarter which saw net profit grow 65.5% to ₹902 crore on revenue of ₹3,080 crore, up 27.8%. EBITDA margin was 40.8% in that quarter, compared to 30.2% a year ago. Profit for the first half comes to ₹2,029 crore when added together.

The summary line in Business Standard reports a 35.4% decline in half-year profit. This is not consistent with the quarterly figures. The calculation of first-half profit a year back is around ₹1,234 crore and the arithmetic suggests it is around 64% growth. The line seems to be a typographical mistake.

The company's position in the market

For all of 2025-26, Divi’s reported total income of ₹11,067 crore and net profit of ₹2,568 crore. More than 79% of last year's full-year profit has been achieved in the first half of the current year.

What caused the margin?

Divi’s makes active pharmaceutical ingredients and custom synthesis products for global drug makers. Profitability was boosted by revenue growth that was significantly in excess of cost growth. Earlier filings attributed the gains to better volumes, cost control and foreign exchange gains, in some quarters.

Growth rate is high on a high base. Investors will monitor any lack of lack of demand for custom synthesis and peptide related work, margin performance, and any resurgences in currency gains. A significant amount of guidance has not been given by the company explicitly in the material reviewed here.

Gland Pharma's net profit increased by 58% to ₹290.75 crore in the same quarter, while other companies have also seen a rise in their quarterly profits. The strength is not exclusively limited to a single company, but varies significantly across companies.